Escolar Documentos
Profissional Documentos
Cultura Documentos
Now that its 2017, we are choosing to write this letter to provide recommendations for best practices to establish
gender diversity as a priority for the biopharma industry.
Last years open letter to the industry sparked a dialogue that led to changes in some company practices, new
training programs, regional gender diversity initiatives and much more. But we believe this is just the start of the
work to be done.
Below is the culmination of recent recommendations collected from industry executives for guiding principles and a
top 10 list of best practices that we believe will continue the momentum of 2016 into 2017 and beyond.
Guiding Principles for Gender Diversity as a Priority for the BioPharma Industry:
We, as community leaders, commit to driving diversity and inclusion in the biopharma industry.
Diversity is good for the business performance of our industry. Research proves that diversity leads to:
Better decision making
Increased productivity and financial performance
Enhanced engagement, recruitment and retention of talent
To ensure that the biopharma industry thrives and is sustainable, we, as community leaders, see it as our
responsibility to drive diversity as a top priority.
Unconscious biases are ubiquitous and difficult to pinpoint and address. Still, we need to make a conscious
commitment to eradicate unconscious biases in recruitment, performance evaluation, promotion and
decision making in order to improve gender diversity.
While we recognize that there are many forms of diversity needed to ensure the future of our industry, there
are clear best practices that can be implemented now to increase gender diversity.
Top Ten Best Practices for Increasing Gender Diversity in the BioPharma Industry:
1.
We as executives and board members declare gender diversity as a priority, as a key value and ethos. We
commit to living it visibly at all of our companies and organizations.
2.
We will create opportunities for open dialogue on enhancing gender diversity and ensuring an inclusive
environment, both within our organizations and across the industry.
3.
We recognize the importance of formal sponsorship programs to ensure diversity in our executive
leadership pipeline and commit to building these programs in our companies.
4.
We also recognize that it is important to provide formal mentorship programs to encourage women to
engage with executives, both inside and outside of our organization. We commit to building these programs
in our companies.
5.
We will ask our board members to be active sponsors of women who are board ready to pursue board
appointments. We will endorse and sponsor our high potential female talent to take part in training
programs to become boardroom ready.
6.
We will measure and track promotion of female talent to senior management positions.
7.
We will seek out and celebrate positive role models within our organizations.
8.
We will review our hiring processes and train our hiring managers on diversity and inclusion as a priority.
9.
We agree with the importance of setting concrete hiring goals to achieve gender parity and inclusion at each
level of our organizations and to measure and report regularly on our progress towards goals.
10. We will support the work of our trade organizations, like MassBio, on industry-wide efforts to improve
gender diversity at the macro level.
We, as community leaders, have the responsibility to ensure our biopharma industry can continue to grow and
thrive. We need to take a holistic view on the next generation of leaders to prepare for the future. We believe that
diversity and inclusion will deliver better results for our industry and society. We have the opportunity and the
responsibility to lead by example, setting the tone and pace for the biopharma industry.
We invite you to join us, to sign this open letter, and to work to implement these practices to ensure the continued
success of our industry.
Robert K. Coughlin
President & CEO
MassBio
Cissy Young
Partner
Russell Reynolds
Abbie Celniker
Partner, Third Rock Ventures
Interim CEO, Goldfinch Bio
Jodie Morrison
CEO and President
Tokai Pharmaceuticals
Steve Woit
Director
BioPharma Executive Council
Susan Windham-Bannister
President & CEO
BioMedical Growth Strategies
Sarah MacDonald
Executive Vice President
MassBio
David Meeker
EVP, General Manager
Sanofi Genzyme
Michael J. Pellini
Chairman
Foundation Medicine
Kate Bingham
Managing Partner
SV Life Sciences
Phillip Sharp
Institute Professor
MIT
Terry McGuire
Founding Partner
Polaris Partners
Ann Stanesa
President
Ten Bridge Communications
Mike OHara
Partner
Deloitte
Lisa Olson
Vice President, Immunology Research & ABC Site Head
AbbVie
Christoph Westphal
CEO
Flex Pharma
Edward Kaye
President, CEO, and Chief Medical Officer
Sarepta Therapeutics
Annalisa Jenkins
CEO
Dimension Therapeutics
Ivana Magovcevic-Liebisch
SVP, Head of Corporate Development
Teva Pharmaceuticals
Steve Kafka
President
Foundation Medicine
Suzanne Bruhn
Director
Pliant Therapeutics & Raptor Pharmaceutical
Travis McCready
President & CEO
Massachusetts Life Sciences Center
Robert Urban
Global Head
Johnson & Johnson Innovation
William McDermott
Partner
McDermott, Quilty & Miller LLP
Scott Gillis
President
Pericor Science, Inc.
Chris Garabedian
Chairman
Xontogeny LLC
Michael D. Ehlers
EVP, Research & Development
Biogen
Christopher de Souza
Director
Broadview Ventures
Geoff Cox
Principal
Beacon St Advisors
Geoff MacKay
President & CEO
AvroBio
Lawrence S. Wittenberg
Senior Partner
Goodwin Procter LLP
James Hoyes
Executive Partner
RxC International
Kumar Srinivasan
VP, Scientific Partnering & Alliances, IMED Biotech Unit
AstraZeneca Pharmaceuticals
Robert Gottlieb
Principal
RMG Associates
Kathleen W. Tregoning
SVP, Corporate Affairs
Biogen
Mark R. Bamforth
President and CEO
Brammer Bio
Antony Loebel
Executive Vice President & Chief Medical Officer
Sunovion Pharmaceuticals Inc.
Robert Ward
CEO
Radius Health
Alice Pomponio
Vice President, Corporate Affairs
Radius Health
Tina Caporale
Managing Director, Audit
Deloitte
Rick Russell
President & CEO
Stallergenes Greer Inc.
Andrea F. Rabney
President and Chief Executive Officer
Argot Partners
Marina Bozilenko
Managing Director
William Blair
Christopher T. Walsh
Professor
Harvard Medical School
Mark Perrin
CEO & Chairman
InVIvo Therapeutics Corporation
Marian Nakada
VP, Venture Investments
Johnson & Johnson Innovation
Eileen Coveney
Managing Director
L.E.K. Consulting
Mike Rice
Founding Partner
LifeSci Advisors
Arthur Hiller
CEO
Antyllus Therapeutics
Adam Gridley
CEO
Histogenics
Nancy Lurker
President & CEO
pSivida
Bob Carpenter
Director
Hydra Biosciences
Bob Linke
President & CEO
Embera NeuroTherapeutics
Alexis Wallace
CEO
Thrombolytic Science
Ailis Tweed-Kent
CEO
Cocoon Biotech
Deniz Kural
CEO
Seven Bridges Genomics
Patrice Milos
CEO
Medley Genomics
Praveen Tipirneni
CEO
Morphic Therapeutic
Jonathan Lewis
CEO
Samus Therpeutics
Paula Soteropoulos
CEO
Akcea Therapeutics
David Moller
VP, BD, Emerging Technology & Innovation
Eli Lilly & Company
Philippe Lopes-Fernandes
SVP, Head of Global Licensing & Business Development
Merck KGaA/Merck Serono
Ed Mascioli
CEO
Karos Pharmaceuticals
Jennifer Wheler
Senior Medical Director
Novartis
Bram Goorden
VP Global Head
Nestle Health Science
Sheila DeWitt
President & CEO
DeuteRx
Doug Kahn
Chairman and CEO
TetraGenetics
Alexis Wallace
CEO
Thrombolytic Science
Laurie Halloran
CEO
Halloran Consulting Group
Lisa McKerracher
CEO
BioAxone BioSciences
Jim Jensen
CEO
CytoSite Biopharma
Michael Schopperle
CEO
CureMeta
Carolyn Green
Director, Strategic Investments
Pfizer
Leslie Williams
CEO
ImmusanT
Deborah Dunsire
Principal
Southern Cross Biotech Consulting
Rosanna Kapeller
Chief Scientific Officer
Nimbus Therapeutics
Patrick Tricoli
CEO
Nanobiotix
Art Krieg
CEO
Checkmate Pharmaceuticals
Bruce Rychlik
Managing Partner
Park Square Executive Search
Anne Deconinck
Executive Director
MIT Koch Institute
Erik Lundh
Managing Partner
Park Square Executive Search
Guy Villax
CEO
Hovione
Tara Schutz
Vice President
Morgan Stanley
Mary Thistle
COO
Dimension Therapeutics
John Mendlein
CEO
ATyr
Kathy Bowdish
Head and VP Global R&D
Sanofi Sunrise
Kathy Williams
Head of Life Sciences
Sunstein, LLP
Jody Rose
Executive Director
New England Venture Capital Association
Chandra Ramanathan
VP and Head East Coast Innovation Center
Bayer, U.S.
Ron Renaud
CEO
RaNa Therapeutics
Vin Milano
CEO
Idera Pharmaceuticals
Joanna Horobin
SVP, Chief Medical Officer
Idera Pharmaceuticals
Marianne De Backer
VP, Johnson & Johnson Innovation
Janssen Business Development
Cat Oyler
VP Strategy and External Innovation
Johnson & Johnson, Janssen Research and Development
Sue Dillon
Global Therapeutic Area Head, Immunology
Johnson & Johnson, Janssen Pharmaceuticals
Marion Dorsch
Chief Scientific Officer
Blueprint Medicines
William Newell
CEO
Sutro Biopharma
Jay Luly
CEO
Enanta Pharmaceuticals
Steve Tregay
CEO
FORMA Therapeutics
Lynn Seeley
CEO
Myovant Sciences
Vivek Ramaswamy
CEO
Roivant Sciences and Axovant Sciences
Alvin Shih
CEO
Enzyvant Sciences
Wendye Robbins
CEO
Blade Therapeutics
Arielle Jackson
Portfolio Director
Boston Biotech Conferences
Elizabeth Franzmann
Chief Scientific Officer
Vigilant Biosciences
John Tagliamonte
Advisor Board Member
WntRx Pharmaceuticals
Filipe Gaspar
VP R&D
Hovione
Jeff Marrazzo
CEO
Spark Therapeutics
John Furey
COO
Spark Therapeutics
Lisa Dalton
Head of Human Resources
Spark Therapeutics
Bonnie Fendrock
CEO
Cyta Therapeutics
Ana Maiques
CEO
Neuroelectrics
Glen Giovannetti
Global Biotechnology Leader
EY
Javier Barrientos
Senior Director, Global Diversity and Inclusion
Biogen